Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON26216
NL-OMON26216
Recruiting
Not Applicable

Everolimus-eluting Bioresorbable Scaffolds for Treatment of Coronary Artery Disease in Patients with Diabetes Mellitus.International, Multicenter, Observational, Prospective Registry Study

Isala Clinics Zwolle0 sites500 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetes Mellitus, Coronary Artery Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Coronary Artery Disease
Sponsor
Isala Clinics Zwolle
Enrollment
500
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Isala Clinics Zwolle

Eligibility Criteria

Inclusion Criteria

  • •Patients aged 18 years or older.
  • •History of DM

Exclusion Criteria

  • •Patients unable to provide informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Not Applicable
Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total OcclusionCoronary Artery Disease
NCT02739685University of Luebeck17
Terminated
Phase 4
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery DiseasePercutaneous Transluminal Coronary Angioplasty
NCT02831205Duk-Woo Park, MD800
Completed
Phase 2
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.polycystic liver disease10019654
NL-OMON32654niversitair Medisch Centrum Sint Radboud44
Active, not recruiting
Phase 1
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver disease
EUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44
Active, not recruiting
Phase 1
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-004550-28-DEAIO-Studien-gGmbH